delpacibart braxlosiran

News

Novartis' $12bn takeover of Avidity could potentially give it the first therapy for genetic disorder facioscapulohumeral muscular dystrophy.

News

With $81.3 million raised, Vogenx is the latest in a staggering summer of biotech IPOs. But the queue past this point looks thin.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.